Right Antidote

Laurus Lab founder Satyanarayana Chava increases stake as the stock loses steam post its weak show in Q4FY18

Sashi Kiran

Hyderabad-based formulations major Laurus Labs has emerged as one of the country's leading manufacturers of active pharmaceutical ingredients (APIs) for anti-retroviral (ARV), Hepatitis C, oncology and other therapeutic segments. Nine out of the 10 largest generic companies in the world are its clients.

However, since the beginning of the year, the stock has lost momentum — coming off 12% against the 3% decline in the Nifty Pharma Index. In fact, with this decline, the stock has given back the gain made in CY17. At its peak in June 2017, the stock had touched Rs.635 but in May this year it traded pretty close to its IPO price of Rs.428, having touched a lo


You don’t want to be left behind. Do you?

Our work is exclusively for discerning readers. To read our edgy stories and access our archives, you’ve to subscribe